Aclaris Therapeutics (NASDAQ:ACRS) Downgraded to “Sell” Rating by Wall Street Zen

Aclaris Therapeutics (NASDAQ:ACRS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities research analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Aclaris Therapeutics in a report on Wednesday, January 28th. Finally, Craig Hallum assumed coverage on shares of Aclaris Therapeutics in a research note on Friday, January 30th. They issued a “buy” rating and a $10.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.80.

Aclaris Therapeutics Stock Performance

ACRS stock opened at $3.06 on Friday. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89. The firm’s fifty day moving average is $3.25 and its 200 day moving average is $2.64. The firm has a market cap of $369.04 million, a PE ratio of -5.77 and a beta of 0.88.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $2.07 million. Research analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ACRS. Raymond James Financial Inc. boosted its position in shares of Aclaris Therapeutics by 2.2% in the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock worth $539,000 after buying an additional 6,217 shares during the period. Rhumbline Advisers grew its position in shares of Aclaris Therapeutics by 7.4% in the 3rd quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 6,271 shares in the last quarter. ProShare Advisors LLC grew its position in shares of Aclaris Therapeutics by 45.4% during the 4th quarter. ProShare Advisors LLC now owns 21,553 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 6,734 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Aclaris Therapeutics by 19.8% during the 4th quarter. Intech Investment Management LLC now owns 46,646 shares of the biotechnology company’s stock valued at $140,000 after buying an additional 7,702 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Aclaris Therapeutics by 59.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 9,894 shares during the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.